Novel biosensors for the detection of estrogen receptor ligands.

De S, Macara IG, Lannigan DA
J Steroid Biochem Mol Biol. 2005 96 (3-4): 235-44

PMID: 15985367 · DOI:10.1016/j.jsbmb.2005.04.030

There exists a significant need for the detection of novel estrogen receptor (ER) ligands for pharmaceutical uses, especially for treating complications associated with menopause. We have developed fluorescence resonance energy transfer (FRET)-based biosensors that permit the direct in vitro detection of ER ligands. These biosensors contain an ER ligand-binding domain (LBD) flanked by the FRET donor fluorophore, cyan fluorescent protein (CFP), and the acceptor fluorophore, yellow fluorescent protein (YFP). The ER-LBD has been modified so that Ala 430 has been changed to Asp, which increases the magnitude of the FRET signal in response to ligand-binding by more than four-fold compared to the wild-type LBD. The binding of agonists can be distinguished from that of antagonists on the basis of the distinct ligand-induced conformations in the ER-LBD. The approach to binding equilibrium occurs within 30min, and the FRET signal is stable over 24h. The biosensor demonstrates a high signal-to-noise, with a Z' value (a statistical determinant of assay quality) of 0.72. The affinity of the ER for different ligands can be determined using a modified version of the biosensor in which a truncated YFP and an enhanced CFP are used. Thus, we have developed platforms for high-throughput screens for the identification of novel estrogen receptor ligands. Moreover, we have demonstrated that this FRET technology can be applied to other nuclear receptors, such as the androgen receptor.

MeSH Terms (13)

Androgens Animals Biosensing Techniques Cercopithecus aethiops COS Cells Fluorescence Resonance Energy Transfer Green Fluorescent Proteins Ligands Mutation Protein Structure, Tertiary Receptors, Androgen Receptors, Estrogen Two-Hybrid System Techniques

Connections (1)

This publication is referenced by other Labnodes entities:

Links